Armata Pharmaceuticals, Inc.
$12.5
▼
-3.6%
2026-04-21 05:23:00
www.armatapharma.com
ASE: ARMP
Explore Armata Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$421.28 M
Current Price
$12.5
52W High / Low
$16.34 / $1.11
Stock P/E
—
Book Value
$-6
Dividend Yield
—
ROCE
-45.96%
ROE
130.37%
Face Value
—
EPS
$-4.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.4
Debt / Equity
-1.32
Current Ratio
1.19
Quick Ratio
1.19
Forward P/E
-7.08
Price / Sales
83.07
Enterprise Value
$686.69 M
EV / EBITDA
-23.13
EV / Revenue
140.03
Rating
Strong Buy
Target Price
$17.5
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 2. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 3. | Atrium Therapeutics, Inc. | $14.3 | — | $239.4 M | — | -32.47% | -104.92% | $73.06 / $11.95 | $-4.04 |
| 4. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
| 5. | Allarity Therapeutics, Inc. | $1.25 | — | $19.46 M | — | -148.49% | -1.04% | $2.35 / $0.77 | $0.61 |
| 6. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 7. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.41 M | -7.78 M | -6.84 M | -8.19 M | -10.54 M | — |
| Net Profit | -124.3 M | -26.68 M | -16.3 M | -6.53 M | 2.6 M | — |
| EPS in Rs | -3.39 | -0.73 | -0.44 | -0.18 | 0.07 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -31.22 M | -42.44 M | -40.89 M | -36.95 M |
| Net Profit | -173.8 M | -18.92 M | -69.05 M | -36.92 M |
| EPS in Rs | -4.74 | -0.52 | -1.88 | -1.01 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 76.88 M | 86.44 M | 98.36 M | 95.83 M |
| Total Liabilities | 295.48 M | 134.46 M | 130.43 M | 59.75 M |
| Equity | -218.6 M | -48.02 M | -32.06 M | 36.08 M |
| Current Assets | 10.67 M | 11.31 M | 19.15 M | 27.05 M |
| Current Liabilities | 8.95 M | 48.25 M | 16.46 M | 24.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -25.76 M | -37.55 M | -47.42 M | -32.48 M |
| Investing CF | -0.54 M | -1.88 M | -8.13 M | -2.21 M |
| Financing CF | 25.61 M | 34.96 M | 53.99 M | 44.02 M |
| Free CF | -26.3 M | -39.43 M | -55.57 M | -34.69 M |
| Capex | -0.54 M | -1.88 M | -8.14 M | -2.21 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 72.6% | -87.03% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.